
SYNAIRGEN PLC
SNG | IL
Overview
Corporate Details
- ISIN(s):
- GB00B0381Z20
- LEI:
- 213800IMMTOPPDF8HD24
- Country:
- United Kingdom
- Address:
- MAILPOINT 810 LEVEL F, SO16 6YD SOUTHAMPTON
- Website:
- https://www.synairgen.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Synairgen is a respiratory biotech company developing inhaled interferon beta (IFN-_) for severe viral lung infections, aiming for a first-of-its-kind, broad-spectrum antiviral treatment delivered directly to the lungs [1].
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-05-16 08:00 |
Board/Management Information
Board and Executive Leadership Changes
|
English | 9.8 KB | |
2025-03-28 15:21 |
Post-Annual General Meeting Information
Result of General Meeting
|
English | 18.6 KB | |
2025-03-11 08:00 |
Pre-Annual General Meeting Information
Proposed cancellation of trading on AIM
|
English | 76.3 KB | |
2025-01-17 13:55 |
Major Shareholding Notification
Holding(s) in Company
|
English | 51.8 KB | |
2025-01-16 16:42 |
Board/Management Information
Martin Murphy appointed as Non-Executive Director
|
English | 17.9 KB | |
2025-01-16 16:42 |
Post-Annual General Meeting Information
Result of General Meeting and Total Voting Rights
|
English | 13.5 KB | |
2025-01-15 18:37 |
Share Issue/Capital Change
£18m raised to fund Phase 2 INVENT clinical trial
|
English | 14.8 KB | |
2024-12-20 08:00 |
Share Issue/Capital Change
Proposed Fundraising
|
English | 398.7 KB | |
2024-10-30 19:09 |
Share Issue/Capital Change
Exercise of Share Options and Total Voting Rights
|
English | 10.5 KB | |
2024-10-10 18:05 |
Post-Annual General Meeting Information
Results of AGM and Appointment of New Chairman
|
English | 10.8 KB | |
2024-09-26 08:00 |
Interim Report
Interim Results
|
English | 143.5 KB | |
2024-09-18 08:00 |
Board/Management Information
Appointment of New Chairman and Notice of AGM
|
English | 17.7 KB | |
2024-09-05 08:00 |
Board/Management Information
Board Change
|
English | 11.1 KB | |
2024-06-27 08:00 |
Earnings Release
2023 Full Year Results
|
English | 129.1 KB | |
2023-11-15 08:00 |
Share Issue/Capital Change
Grant of Options
|
English | 28.7 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
![]() |
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
![]() |
Aptahem AB | Sweden | APTA | |
![]() |
Arctic Bioscience | Norway | ABS | |
![]() |
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
![]() |
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
![]() |
AroCell AB | Sweden | AROC | |
![]() |
Arterra Bioscience | Italy | ABS |